Catalyst Pharmaceutical Partners Inc. (CPRX)
-NasdaqCM 0.88 
0.04(5.38%) May 24, 3:57PM EDT
| Prev Close: | 0.84 |
|---|
| Open: | 0.85 |
|---|
| Bid: | 0.80 x 1000 |
|---|
| Ask: | 1.00 x 100 |
|---|
| 1y Target Est: | 2.25 |
|---|
| Beta: | 0.67 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.82 - 0.88 |
|---|
| 52wk Range: | 0.37 - 2.27 |
|---|
| Volume: | 175,045 |
|---|
| Avg Vol (3m): | 741,066 |
|---|
| Market Cap: | 36.45M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.14 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CATALYST PHARMACEUTICAL PARTNERS, INC. FinancialsEDGAR Online Financials(Tue, May 21)
- Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pillat Seeking Alpha(Mon, May 20)
- Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, May 16)
- CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- Dr. Reddy's Earnings Increase Y/YZacks(Wed, May 15)
- FDA Accepts Merck BLAZacks(Wed, May 15)
- CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- Forest-Trevena Ink DealZacks(Tue, May 14)
- Jazz Pharma Posts Higher Y/Y EarningsZacks(Tue, May 14)
- Salix Beats on EarningsZacks(Tue, May 14)
- Narrower-than-Expected Loss at SupernusZacks(Tue, May 14)
- Glaxo/THRX's Breo Ellipta Gets FDA NodZacks(Mon, May 13)
- Wider-Than-Expected Loss at AnacorZacks(Mon, May 13)
- Pacira Reports Wider LossZacks(Fri, May 10)
- Wider-than-Expected Loss at AvanirZacks(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.25 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases ...
View More